Computational Methods in Road towards Drug Discovery against SARS-CoV2

CoV) Initially, it was considered a spill-over and that 3 . the infection was disseminated into the local pool by animal-to-human contact; however, later human-to4 human transmission was confirmed in patients with n-CoV in the southern part of China. The genome of the virus is around 30 kb encoding 15 proteins. As, SARS-CoV2 has emerged recently, there is currently no drug or vaccine available to combat 4 this deadly pandemic. The high number of deaths associated with the virus is because of lack of treatment for SARS-CoV2. Therefore, the development of a seamless, smooth and quick process for the discovery of drugs against the virus is the need of the day. The identification of novel drug compound is drug discovery. This is a complex process as it involves various fields of sciences apart from being laborious and time-consuming process. It is for this reason numerous techniques of virtual screening were introduced in order to overcome the delays that usually hampers the development of 5-8 drugs. For example, using virtual screening some of the protein structures of SARs-CoV2 have been stored in the protein data bank, and further structure can be added to the data bank via computational analysis. This review article summarizes the drug design via virtual screening based on their structure, ligand interactions with their receptors and the analysis of their potential efficacy against SARsCoV2. Introduction The novel coronavirus has affected more than 24 million people across the world including 6.7 million active cases, 61,400 critical cases and 835,679 deaths have been reported by the World Health , Organization (WHO), till date. In order to track the 1 2

[1]  P. Ehrlich Über den jetzigen Stand der Chemotherapie , 1909 .

[2]  P. Gund Three-Dimensional Pharmacophoric Pattern Searching , 1977 .

[3]  R. Rhoads,et al.  Progress in Molecular and Subcellular Biology , 1990, Progress in Molecular and Subcellular Biology.

[4]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[5]  M. Buchmeier,et al.  Coronavirus Spike Proteins in Viral Entry and Pathogenesis , 2001, Virology.

[6]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[7]  D. X. Liu,et al.  Coronavirus envelope protein: A small membrane protein with multiple functions , 2007, Cellular and Molecular Life Sciences.

[8]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[9]  Sheng-Yong Yang,et al.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.

[10]  C. Machamer,et al.  The Hydrophobic Domain of Infectious Bronchitis Virus E Protein Alters the Host Secretory Pathway and Is Important for Release of Infectious Virus , 2010, Journal of Virology.

[11]  J. Schwartz,et al.  Homology Model Versus X-ray Structure in Receptor-based Drug Design: A Retrospective Analysis with the Dopamine D3 Receptor. , 2011, ACS medicinal chemistry letters.

[12]  I. Wilson,et al.  A structural analysis of M protein in coronavirus assembly and morphology , 2010, Journal of Structural Biology.

[13]  K. Jacobson,et al.  New Insights for Drug Design from the X-Ray Crystallographic Structures of G-Protein-Coupled Receptors , 2012, Molecular Pharmacology.

[14]  B. Fielding,et al.  The Coronavirus Nucleocapsid Is a Multifunctional Protein , 2014, Viruses.

[15]  Haitao Yang,et al.  Recent progress in the discovery of inhibitors targeting coronavirus proteases , 2016, Virologica Sinica.

[16]  Leonardo L. G. Ferreira,et al.  Molecular Docking and Structure-Based Drug Design Strategies , 2015, Molecules.

[17]  Tao Wang,et al.  Advances in Computational Structure-Based Drug Design and Application in Drug Discovery. , 2015, Current topics in medicinal chemistry.

[18]  S. Marshall,et al.  Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation , 2016, CPT: pharmacometrics & systems pharmacology.

[19]  Sun Choi,et al.  Expediting the Design, Discovery and Development of Anticancer Drugs using Computational Approaches. , 2017, Current medicinal chemistry.

[20]  Thomas Seidel,et al.  3D Pharmacophore Modeling Techniques in Computer‐Aided Molecular Design Using LigandScout , 2017 .

[21]  John B. O. Mitchell,et al.  Rational drug design of antineoplastic agents using 3D-QSAR, cheminformatic, and virtual screening approaches. , 2019, Current medicinal chemistry.

[22]  J. Ziller,et al.  X-ray crystallographic structure of a teixobactin analogue reveals key interactions of the teixobactin pharmacophore. , 2017, Chemical communications.

[23]  T. Fung,et al.  Post-translational modifications of coronavirus proteins: roles and function , 2018, Future virology.

[24]  S. Perlman,et al.  Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis , 2018, mBio.

[25]  R. Kist,et al.  Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of rapamycin binding site. , 2017, Journal of molecular graphics & modelling.

[26]  Gaoqi He,et al.  An Improved Receptor-Based Pharmacophore Generation Algorithm Guided by Atomic Chemical Characteristics and Hybridization Types , 2018, Front. Pharmacol..

[27]  M. Heller,et al.  Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling , 2018, eLife.

[28]  K. Sankaranarayanan,et al.  Identification of potential CRAC channel inhibitors: Pharmacophore mapping, 3D-QSAR modelling, and molecular docking approach , 2019, SAR and QSAR in environmental research.

[29]  Entedar A J Alsaadi,et al.  Membrane binding proteins of coronaviruses , 2019, Future virology.

[30]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[31]  Lisa E. Gralinski,et al.  Return of the Coronavirus: 2019-nCoV , 2020, Viruses.

[32]  A. Godzik,et al.  Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐CoV‐2 , 2020, bioRxiv.

[33]  Bhumi M. Shah,et al.  In silico studies on therapeutic agents for COVID-19: Drug repurposing approach , 2020, Life Sciences.

[34]  U. Jha,et al.  A review of the 2019 novel coronavirus (COVID-19) based on current evidence , 2020 .

[35]  Sumra Wajid Abbasi,et al.  Stilbene-based natural compounds as promising drug candidates against COVID-19 , 2020, Journal of biomolecular structure & dynamics.

[36]  Junmei Wang,et al.  Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study , 2020, Journal of chemical information and modeling.

[37]  Suresh Kumar Drug and Vaccine Design against Novel Coronavirus (2019-nCoV) Spike Protein through Computational Approach , 2020 .

[38]  Sairaj Satarker,et al.  Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2 , 2020, Archives of Medical Research.

[39]  Xiaoqian Lin,et al.  A Review on Applications of Computational Methods in Drug Screening and Design , 2020, Molecules.

[40]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[41]  Jane Parr Pneumonia in China: lack of information raises concerns among Hong Kong health workers. , 2020, BMJ.

[42]  B. Medhi,et al.  Drug targets for corona virus: A systematic review , 2020, Indian journal of pharmacology.

[43]  Sk Abdul Amin,et al.  Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors , 2020, Journal of biomolecular structure & dynamics.

[44]  G. Gao,et al.  A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020 , 2020, China CDC weekly.

[45]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[46]  Jiachen Sun,et al.  A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019‐nCoV) , 2020, Journal of medical virology.

[47]  Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock , 2020, VirusDisease.

[48]  M. Roser,et al.  Coronavirus Pandemic (COVID-19) , 2020 .

[49]  Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐CoV‐2 , 2020, Protein science : a publication of the Protein Society.

[50]  L. Guddat,et al.  Structure of the RNA-dependent RNA polymerase from COVID-19 virus , 2020, Science.

[51]  R. Hilgenfeld,et al.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.